New hope in the fight against malaria?

Future Medicinal Chemistry

Volumn 3, Issue 1, 2011, Pages 1-3

  Rodrigues, Tiago ^a   Moreira, Rui ^a   Lopes, Francisca ^a  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

Author keywords

high throughput screening; liver stage; malaria; mitochondrial electron transport chain

Indexed keywords

ANTIMALARIAL AGENT; MK 4815; NITD 609; UNCLASSIFIED DRUG;

DRUG INDUSTRY; EDITORIAL; HUMAN; IC 50; LIFE CYCLE; MALARIA; MALARIA CONTROL; PARASITE LOAD; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

ANTIMALARIALS; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LIVER; MALARIA; PLASMODIUM;

EID: 78650654244     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.274     Document Type: Editorial

References (15)

1. Carrara VI, Zwang J, Ashley EA et al. Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PloS One 4(2), e4551 (2009).
2. Ekland EH, Fidock DA. In vitro evaluations of antimalarial drugs and their relevance to clinical outcomes. Int. J. Parasitol. 38(7), 743-747 (2008).
3. Rottmann M, McNamara C, Yeung BKS et al. Spiroindolones, a potent compound class for the treatment of malaria. Science 329(3), 1175-1180 (2010).
4. Gamo FJ, Sanz LM, Vidal J et al. Thousands of chemical starting points for antimalarial lead identification. Nature 465(7296), 305-310 (2010).
5. Guiguemde WA, Shelat AA, Bouck D et al. Chemical genetics of Plasmodium falciparum. Nature 465(7296), 311-315 (2010).
6. Wells TNC, Alonso PL, Gutteridge W. New medicines to improve control and contribute to the eradication of malaria. Nat. Rev. Drug Discov. 8(11), 879-891 (2009).
7. Gujjar R, Marwaha A, Mazouni FE et al. Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice. J. Med. Chem. 52(7), 1864-1872 (2009)
8. Phillips MA, Gujjar R, Malmquist NA et al. Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite Plasmodium falciparum. J. Med. Chem. 51(12), 3649-3653 (2008).
9. Baldwin J, Michnoff CH, Malmquist NA et al. High-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. J. Biol. Chem. 280(23), 21847-21853 (2005).
10. Gardner MJ, Hall N, Fung E et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 419(6906), 498-511 (2002).
11. Rodrigues T, Lopes F, Moreira R. Inhibitors of the mitochondrial electron transport chain and de novo pyrimidine biosynthesis as antimalarials: the present status. Curr. Med. Chem. 17(10), 929-956 (2010).
12. Prudêncio M, Rodriguez A, Mota MM. The silent path to thousands of merozoites: the Plasmodium liver stage. Nat. Rev. Microbiol. 4(11), 849-856 (2006).
13. Cunha-Rodrigues M, Prudêncio M, Mota MM, Haas W. Antimalarial drugs-host targets (re)visited. Biotechnol. J. 1(3), 321-332 (2006).
14. Mahmoudi N, Garcia-Domenech R, Galvez J et al. New active drugs against liver stages of plasmodium predicted by molecular topology. Antimicrob. Agents Chemother. 52(4), 1215-1220 (2008).
15. Albuquerque SS, Carret C, Grosso AR et al. Host cell transcriptional profiling during malaria liver stage infection reveals a coordinated and sequential set of biological events. BMC Genomics 10, 270 (2009).